Search company, investor...

Founded Year

2011

Stage

Debt | Alive

Total Raised

$26.71M

Last Raised

$3.45M | 3 yrs ago

About OncoSynergy

OncoSynergy develops immunotherapies to improve outcomes for cancer patients. It provides solutions for treatment-resistant cancer through resistance mechanism inhibitors (RMIs) that inhibit several cancer-driving pathways simultaneously. The company was founded in 2011 and is based in Stamford, Connecticut.

Headquarters Location

850 Pacific Street Unit 1802

Stamford, Connecticut, 06903,

United States

415-299-4249

Loading...

Loading...

OncoSynergy Patents

OncoSynergy has filed 5 patents.

The 3 most popular patent topics include:

  • clusters of differentiation
  • immune system
  • immunology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/12/2018

10/12/2021

Experimental cancer drugs, Oncology, Clusters of differentiation, Monoclonal antibodies, Transcription factors

Grant

Application Date

7/12/2018

Grant Date

10/12/2021

Title

Related Topics

Experimental cancer drugs, Oncology, Clusters of differentiation, Monoclonal antibodies, Transcription factors

Status

Grant

Latest OncoSynergy News

Glioblastoma Pipeline, Clinical Trials, FDA Approvals, Research and Developments, Future Perspectives, and Companies (Updated)

Jan 9, 2024

Posted on DelveInsight’s, “Glioblastoma Pipeline Insight 2023” report provides comprehensive insights about 195+ companies and 210+ pipeline drugs in the Glioblastoma pipeline landscape. It covers the Glioblastoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Glioblastoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Key Takeaways from the Glioblastoma Pipeline Report DelveInsight’s Glioblastoma pipeline report depicts a robust space with 195+ active players working to develop 210+ pipeline therapies for Glioblastoma treatment. The leading Glioblastoma Companies working in the market include Denovo BioPharma, Pfizer, Vigeo Therapeutics, Celldex Therapeutics, Debiopharm, Prelude Therapeutics, AiVita Biomedical, Ascletis Pharma, Kintara Therapeutics, Bayer AG, Kazia Therapeutics, GlaxoSmithKline, Candel Therapeutics, Symphogen A/S, Sanofi, Oblato, Jiangsu Hengrui Medicine, BPGbio, Inc., Alaunos Therapeutics, Eli Lilly and Company, Actuate Therapeutics, Oncotelic Therapeutics, The Menarini Group, SonALAsense, Novartis, Allarity Therapeutics, PharmAbcine, I-Mab Biopharma Co. Ltd., Aadi Bioscience Inc., Matrix Biomed, Photonamic GmbH & Co. KG, Lixte, Black Diamond Therapeutics, Tmunity Therapeutics, SOM Biotech, Moleculin, Xynomic Pharmaceuticals, OncoSynergy, and others. Promising Glioblastoma Pipeline Therapies in the various stages of development include Azeliragon, PLX3397, Temozolomide, VXM01, Avelumab, Cilengitide, LAM561, Onfekafusp Alfa, and others. January 2024: Hoffmann-La Roche announced a study of Phase 1 clinical trials for RO7428731. This is an open-label, multicenter study to assess safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD), and preliminary efficacy of RO7428731 administered as a monotherapy in participants with newly diagnosed or recurrent epidermal growth factor receptor variant III (EGFRvIII)-positive glioblastoma (GBM). December 2023: Boehringer Ingelheim announced a study of Phase 1 clinical trials for BI 907828 (Brigimadlin). This study is open to adults with newly diagnosed glioblastoma, a type of brain tumor. The study has two parts. Part 1 is open to people who can get their brain tumor removed by surgery. Part 2 is open to people who already had such a brain surgery. December 2023: Eli Lilly and Company announced a study of Phase 2 clinical trials for LY2157299 monohydrate, and Lomustine. The purpose of the study is to see whether treatment with LY2157299 on its own, LY2157299 plus lomustine therapy or lomustine plus placebo can help participants with brain cancer. December 2023: Cantex Pharmaceuticals announced a study of Phase 2 clinical trials for Azeliragon. This is a phase 2 study to evaluate the safety and preliminary evidence of effectiveness of azeliragon, in combination with radiation therapy, as an initial treatment of a form of glioblastoma. Glioblastoma is a type of brain cancer that grows quickly and can invade and destroy healthy tissue. There’s no cure for glioblastoma, which is also known as glioblastoma multiforme. December 2023: Enterome announced a study of Phase 1 & 2 clinical trials for Multiple dose of EO2401. The purpose of this study is to assess the safety, tolerability, immunogenicity, and preliminary efficacy of EO2401 in patients with unequivocal evidence of progressive or first recurrent glioblastoma. In the Glioblastoma Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Glioblastoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details. The assessment part of the report embraces, in depth Glioblastoma commercial assessment and clinical assessment of the Glioblastoma pipeline products under development. Glioblastoma Overview The glioblastoma multiforme preferentially invades along myelinated axons, vascular basement membranes, and the subependyma, mostly occurring in the subcortical matter of the cerebrum (65%). Within the cerebrum, the tumors proliferate through the temporal (31%), parietal (24%), frontal (23%), and occipital (16%) lobes. However, tumor formation is rarely isolated exclusively to one of these lobes, instead presenting in a combination of these lobes within the cerebrum. GBM also forms in the hypothalamus-thalamus area (20%) and the cerebellum and posterior fossa (15%). Glioblastoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Glioblastoma Companies- Denovo BioPharma, Pfizer, Vigeo Therapeutics, Celldex Therapeutics, Debiopharm, Prelude Therapeutics, AiVita Biomedical, Ascletis Pharma, Kintara Therapeutics, Bayer AG, Kazia Therapeutics, GlaxoSmithKline, Candel Therapeutics, Symphogen A/S, Sanofi, Oblato, Jiangsu Hengrui Medicine, BPGbio, Inc., Alaunos Therapeutics, Eli Lilly and Company, Actuate Therapeutics, Oncotelic Therapeutics, The Menarini Group, SonALAsense, Novartis, Allarity Therapeutics, PharmAbcine, I-Mab Biopharma Co. Ltd., Aadi Bioscience Inc., Matrix Biomed, Photonamic GmbH & Co. KG, Lixte, Black Diamond Therapeutics, Tmunity Therapeutics, SOM Biotech, Moleculin, Xynomic Pharmaceuticals, OncoSynergy, and others. Glioblastoma Pipeline Therapies- Azeliragon, PLX3397, Temozolomide, VXM01, Avelumab, Cilengitide, LAM561, Onfekafusp Alfa, and others.

OncoSynergy Frequently Asked Questions (FAQ)

  • When was OncoSynergy founded?

    OncoSynergy was founded in 2011.

  • Where is OncoSynergy's headquarters?

    OncoSynergy's headquarters is located at 850 Pacific Street Unit 1802, Stamford.

  • What is OncoSynergy's latest funding round?

    OncoSynergy's latest funding round is Debt.

  • How much did OncoSynergy raise?

    OncoSynergy raised a total of $26.71M.

  • Who are the investors of OncoSynergy?

    Investors of OncoSynergy include Connecticut Innovations, Korea.net, NLabs, JLabs and University of California, San Francisco.

Loading...

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.